|
|
| | Benzeneacetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-α-methyl-4-(2-oxo-1-pyrrolidinyl)-, (αS)- Basic information |
| | Benzeneacetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-α-methyl-4-(2-oxo-1-pyrrolidinyl)-, (αS)- Chemical Properties |
| Boiling point | 722.6±60.0 °C(predicted) | | density | 1.348±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 13.43±0.10(predicted) |
| | Benzeneacetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-α-methyl-4-(2-oxo-1-pyrrolidinyl)-, (αS)- Usage And Synthesis |
| Uses | (S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice[1]. | | References | [1] Vihma H, et al. Ube3a unsilencer for the potential treatment of Angelman syndrome. Nat Commun. 2024 Jul 8;15(1):5558. DOI:10.1038/s41467-024-49788-8 |
| | Benzeneacetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-α-methyl-4-(2-oxo-1-pyrrolidinyl)-, (αS)- Preparation Products And Raw materials |
|